Insights

Strategic Focus ANEUVO specializes in non-invasive neuromodulation for disabling diseases and conditions not addressed by traditional pharmaceuticals, presenting a targeted sales opportunity with a unique value proposition in bioelectronic medicine and SCI therapy.

Regulatory Milestones ExaStim is CE marked and FDA 510(k) cleared, signaling credible safety and efficacy in key markets. This enables accelerated outreach to healthcare providers, rehabilitation centers, and payers in the US and EU.

Market Validation Recent awards and international recognition, including Taiwan’s National Innovation Award and participation in RehaCare ISCoS events, bolster credibility for global expansion and partnerships with medical device distributors.

Funding Momentum Series C financing and multi-market visibility suggest growing investor confidence and potential capital to support clinical studies, payer negotiations, and scaled sales efforts.

Target Customer Fit Small to mid-sized medical technology and rehab centers focusing on spinal cord injury and neuromodulation represent primary customers, with opportunities to partner with larger contract research organizations and distributors seeking innovative device portfolios.

Similar companies to ANEUVO

ANEUVO Tech Stack

ANEUVO uses 8 technology products and services including Google Ads, Apache Kafka, Amazon Web Services, and more. Explore ANEUVO's tech stack below.

Media & News

ANEUVO's Email Address Formats

ANEUVO uses at least 4 email formats:
ANEUVO Email FormatsExamplePercentage
First@aneuvo.comJohn@aneuvo.com
50%
FirstL@aneuvo.comJohnD@aneuvo.com
25%
FLast@aneuvo.comJDoe@aneuvo.com
25%
First@nichebio.comJohn@nichebio.com
100%

Frequently Asked Questions

What is ANEUVO's official website and social media links?

Minus sign iconPlus sign icon
ANEUVO's official website is aneuvo.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ANEUVO generate?

Minus sign iconPlus sign icon
As of August 2026, ANEUVO's annual revenue is estimated to be $1M - $10M.

What is ANEUVO's NAICS code?

Minus sign iconPlus sign icon
ANEUVO's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does ANEUVO have currently?

Minus sign iconPlus sign icon
As of August 2026, ANEUVO has approximately 28 employees across 4 continents, including North America, Asia and Europe. Key team members include Vice President Of Operations And Sales, Imaging: L. R. and Advisory Board Member: B. M. Explore ANEUVO's employee directory with LeadIQ.

What industry does ANEUVO belong to?

Minus sign iconPlus sign icon
ANEUVO operates in the Medical Equipment Manufacturing industry.

What technology does ANEUVO use?

Minus sign iconPlus sign icon
ANEUVO's tech stack includes Google Ads, Apache Kafka, Amazon Web Services, Microsoft SharePoint, WordPress, Microsoft Azure, Bitbucket and LabVIEW.

What is ANEUVO's email format?

Minus sign iconPlus sign icon
ANEUVO's email format typically follows the pattern of First@aneuvo.com. Find more ANEUVO email formats with LeadIQ.

How much funding has ANEUVO raised to date?

Minus sign iconPlus sign icon
As of August 2026, ANEUVO has raised $23M in funding. The last funding round occurred on Mar 05, 2026.
ANEUVO logo

ANEUVO

Medical Equipment ManufacturingCalifornia, United States11-50 Employees

ANEUVO is a medical equipment manufacturing company based in Los Angeles, California, focused on developing platform-based therapies for disabling diseases and conditions that have not responded to traditional pharmaceutical approaches. Its ExaStim® Stimulation System is a non-invasive neuromodulation device that has received regulatory designations indicating potential use in treating spinal cord injury, though its clearance is limited to Europe and it remains investigational in the United States. The company operates within the medical technology sector, aiming to address unmet needs through neuromodulation therapies that may complement or offer alternatives to existing treatments for SCI patients.

Targeting patients with spinal cord injury and related conditions, ANEUVO emphasizes non-invasive approaches designed to stimulate neural activity and support rehabilitation. The organization positions itself as a development platform in medical technology, pursuing therapies that have progressed through regulatory pathways and are presented at industry events, with a focus on advancing non-invasive neuromodulation for SCI. The company is described as having a presence in the Los Angeles area and operates as a smaller enterprise within the broader medical device landscape.

Section iconCompany Overview

Website
aneuvo.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $23M

    ANEUVO has raised a total of $23M of funding over 7 rounds. Their latest funding round was raised on Mar 05, 2026 as a Series C.

  • $1M - $10M

    ANEUVO's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.